A Drug-drug Interaction Trial of Rifampicin Pharmacokinetics Effect on Fluzoparib

NCT04011124 | Completed Phase 1

• 1 other identifier: FZPL-I-110
• Study Type: interventional
• Target: 16
• Locations: 1 country
• Sites: 1

Brief Summary

The primary objective of the study was to assess the effect of repeated oral doses of Rifampicin on the pharmacokinetic profile of a single dose of Fluzoparib. The secondary objective of the study was to assess the safety of Fluzoparib given alone versus Fluzoparib coadministered with Rifampicin.

Conditions

Healthy Male Subjects

Outcome Measures

Primary Outcomes (2)

• Peak Plasma Concentration (Cmax) of Fluzoparib

  Day 1 to Day 15

• Area under the plasma concentration versus time curve (AUC) of Fluzoparib

  Day 1 to Day 15

Secondary Outcomes (1)

• Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

  Up to Day 22

Study Arms (1)

Rifampicin + Fluzoparib

EXPERIMENTAL

Drug: Fluzoparib; Drug: Rifampicin

Interventions

Fluzoparib DRUG

single dose on Day 1 and Day 12

Rifampicin + Fluzoparib

Rifampicin DRUG

QD on Day 5-14 for 10 days

Rifampicin + Fluzoparib

Eligibility Criteria

• Age: 18 Years - 50 Years
• Sex: male
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64)

You may qualify if:

• Sign the informed consent form before the trial and fully understand the trial content, process and possible adverse reactions;
• Ability to complete the study as required by the protocol;
• Age on the date of signing the informed consent form is 18 to 50 years old (including both ends) and is limited to male subjects only;
• Male subjects are willing to have no birth plans in the next 6 months and voluntarily take effective contraception;
• The fasting weight is not less than 50kg, and the body mass index (BMI) is in the range of 18 kg/m2 to 28 kg/m2 (including both ends);
• Health status: no medical history of heart, liver, kidney, digestive tract, nervous system, mental abnormalities and metabolic abnormalities;
• Accepted physical examination results (vital signs, physical examination) and routine laboratory examination (blood routine, blood biochemistry, urine routine, etc.), 12-lead ECG, X-chest, abdominal B-ultrasound, etc. or no clinical significance if abnormal.
• Creatinine clearance (CLCr) ≥ 80 mL/min, and creatinine is less than or equal to the upper limit of normal

You may not qualify if:

• Participate in blood donation within 3 months before screening and donate blood volume ≥400mL or blood loss ≥400mL, participate in blood donation within 1 month before screening and donate blood volume ≥200mL or blood loss ≥200mL, or receive blood transfusion;
• Allergic constitution, including a history of severe drug allergy or drug allergy; a history of allergies to fluzoparib capsule or its excipients;
• with drug and/or alcohol abuse history, or alcohol, nicotine and drug screening positives, or drug abuse in the past five years or used drugs 3 months before the trial; and could not prohibit smoking and alcohol during the trial period ;
• with medical history of cardiovascular disease such as myocarditis, coronary heart disease, pathological arrhythmia, and stroke;
• Pulmonary diseases, including invasive lung disease, pneumonia, dyspnea, etc.;
• Chronic kidney disease, renal insufficiency, history of renal anemia;
• have a history of dysphagia or any history of gastrointestinal disease that affects drug absorption;
• any uncontrolled peptic ulcer, colitis, pancreatitis, etc.;
• Anyone who has undergone any surgery within the first 6 months of screening; has undergone any surgery that affects gastrointestinal absorption (including gastrectomy, bowel resection, stomach reduction, etc.);
• with acute disease that has been clinically determined by the investigator occurred within 1 month before screening;
• Other important organ diseases such as the nervous system, cardiovascular system, urinary system, digestive system, respiratory system, metabolic and musculoskeletal system with clear medical history (such as uncontrolled diabetes, high blood pressure, etc.), enabling investigators considered unsuitable for participation in the study;
• Those who have taken any clinical trial drugs within 3 months;
• Take any drug that affects liver metabolism within 28 days before taking the investigational drug;
• Take any prescription or over-the-counter medication within 14 days before taking the investigational drug;
• Take any vitamin products or herbs within 14 days before taking the investigational drug;

Sponsors & Collaborators

• Jiangsu HengRui Medicine Co., Ltd.: lead

Study Sites (1)

First Affiliated Hospital of Zhejiang University School of Medicine

Hangzhou, Zhejiang, 310003, China

Location

MeSH Terms

Interventions

fluzoparib; Rifampin

Intervention Hierarchy (Ancestors)

Rifamycins; Heterocyclic Compounds, 4 or More Rings; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Lactams, Macrocyclic; Macrocyclic Compounds; Polycyclic Compounds

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: July 3, 2019
• First Posted: July 8, 2019
• Study Start: July 24, 2019
• Primary Completion: September 16, 2019
• Study Completion: September 16, 2019
• Last Updated: February 26, 2020

Record last verified: 2020-02

Locations

CN (1)